Cytarabine

BreastfeedingPediatric
  • TRADE NAMES: Alexan; Arabitin; Arace; Aracytine; Cytarbel; Cytosar; Cytosar-U (Sicor); DepoCyt (Pacira); Uducil
  • INDICATIONS: Leukemias
  • SYNONYM: ara-C
  • CLASS: Antimetabolite, Antineoplastic, Antiviral
  • HALF-LIFE: initial: 10–15 minutes
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Aldesleukin

PREGNANCY CATEGORY: D

DepoCyt is a liposomal formulation.

Vasculitis, a part of the cytarabine syndrome, consists of fever, malaise, myalgia, conjunctivitis, arthralgia and a diffuse erythematous maculopapular eruption that occurs from 6–12 hours following the administration of the drug.

DepoCyt: CHEMICAL ARACHNOIDITIS ADVERSE REACTIONS

See full prescribing information for complete boxed warning.

Our database has 106 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
NAILS
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
RENAL
HEMATOLOGIC
OCULAR
LOCAL
OTHER


Page last updated 03/20/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric